Speaking the same language: international cross-validation of emerging biomarkers for juvenile idiopathic arthritis and Still’s Disease
Authors' conclusion
We demonstrate substantial differences in the quantification of standardized biomarker concentrations both between assay types and across testing sites. In contrast, analyses of real-world samples from sJIA patients showed high concordance between two independent Ella platforms, indicating that this platform could improve clinical and research standardization.
Study context
- Population
- Recombinant IL-18, CXCL9, S100A8/9 and S100A12 spiked into donor human serum; samples from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) FROST study (sJIA)
- Comparison
- Biomarker measurement platforms (ELISA, Luminex, Ella) across centres in Europe (EU) and North America, before and after mathematical correction
- Outcome
- Comparability of biomarker measurements across platforms
Methodological detailsblinded spiked samples, international multicentre, validation on FROST study samples
- Blinded spiked samples
- International multicentre
- Validation on FROST study samples
Performance
As reported in the abstract
IL-18 in spiked samples: overall strong correlation across platforms, but significant analytical variation in percent recovery
≈50-400%
Original publication
Speaking the same language: international cross-validation of emerging biomarkers for juvenile idiopathic arthritis and Still’s Disease. Pediatr Rheumatol Online J. Published 9 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →